openRxiv
Ingestible capsule for detecting labile inflammatory biomarkers in situ
Publication
, Preprint
Inda, ME; Jimenez, M; Liu, Q; Phan, NV; Ahn, J; Steiger, C; Wentworth, A; Riaz, A; Zirtiloglu, T; Wong, K; Ishida, K; Fabian, N; Jenkins, J ...
February 16, 2022
Duke Scholars
Citation
APA
Chicago
ICMJE
MLA
NLM
Inda, M. E., Jimenez, M., Liu, Q., Phan, N. V., Ahn, J., Steiger, C., … Lu, T. K. (2022). Ingestible capsule for detecting labile inflammatory biomarkers in situ. openRxiv. https://doi.org/10.1101/2022.02.16.480562
Inda, M. E., M. Jimenez, Q. Liu, N. V. Phan, J. Ahn, C. Steiger, A. Wentworth, et al. “Ingestible capsule for detecting labile inflammatory biomarkers in situ.” OpenRxiv, February 16, 2022. https://doi.org/10.1101/2022.02.16.480562.
Inda ME, Jimenez M, Liu Q, Phan NV, Ahn J, Steiger C, et al. Ingestible capsule for detecting labile inflammatory biomarkers in situ. openRxiv. 2022.
Inda, M. E., et al. “Ingestible capsule for detecting labile inflammatory biomarkers in situ.” OpenRxiv, 16 Feb. 2022. Crossref, doi:10.1101/2022.02.16.480562.
Inda ME, Jimenez M, Liu Q, Phan NV, Ahn J, Steiger C, Wentworth A, Riaz A, Zirtiloglu T, Wong K, Ishida K, Fabian N, Jenkins J, Kuosmanen J, Madani W, McNally R, Lai Y, Hayward A, Mimee M, Nadeau P, Chandrakasan AP, Traverso G, Yazicigil RT, Lu TK. Ingestible capsule for detecting labile inflammatory biomarkers in situ. openRxiv. 2022.